AdvanCell Successfully Completes an Oversubscribed US$112M Series C Financing

Long-term NIF user and collaborator, AdvanCell which has secured $112m in Series C funding supported by Sanofi Ventures to advance its targeted alpha therapy for metastatic prostate cancer.

Read the full statement from AdvanCell

Read more about how NIF has supported AdvanCell in testing the promising new prostate cancer therapy drug, which was administered to its first patient in a clinical trial last year.